¿ Bioject Medical Technologies Inc., of Portland, Ore., said it completed a round of private equity financing, netting the company about $10.5 million from the sale of approximately 1.4 million shares of common stock at a price of $7.88 per share. Lone Pine Capital, of Greenwich, Conn., led the five-investor financing.
¿ Cel-Sci Corp., of Vienna, Va., said clinical study results of the company's anticancer immunotherapy drug, Multikine, indicated positive immune system response in the treatment of head and neck cancer. The study results were reported at the 5th International Congress on Head and Neck Cancer in San Francisco. In the two-week, 12-patient study, tumor measurements were reduced in varying degrees in all patients. Several patients were afforded increased tongue mobility and/or pain reduction, and increased immune responses were measured in several of the patients.
¿ Cypress Bioscience Inc., of San Diego, said it will expand a pilot program in conjunction with Fresenius Medical Care North America to facilitate delivery of apheresis treatents using the company's Prosorba column, indicated for use for reduction of the symptoms of moderate to severe rheumatoid arthritis. Fresenius will purchase 1,000 columns in the remaining quarters of this year in addition to the 1,000 purchased in June.
¿ DNAPrint Inc., of Sarasota, Fla., said it entered an agreement with Geospiza Inc., of Seattle, covering beta testing of Geospiza's DNA sequence information management system for standard DNA sequencing files. DNAPrint became one of a small group of organizations using the Internet-based relational database structured-system, called Finch-Server, for testing purposes. DNAPrint will use the system for SNP location re-sequencing and standard DNA sequence data communication.
¿ Icos Corp., of Bothell, Wash., said it expanded its year-old drug discovery collaboration with Array BioPharma Inc., of Boulder, Colo., to include process research and manufacturing. Icos has worldwide development and marketing rights to any products resulting from the collaboration, and will pay Array BioPharma milestones connected to the commercialization of collaborative products. The move results from the identification of a PDE4 inhibitor seen as a clinical candidate.
¿ Proteome Inc., of Beverly, Mass., said it has released PombePD, its proprietary database for the fission yeast Schizosaccharomyces pombe, a model organism for human disease in cell cycle research and cancer biology. The database will become part of the company's BioKnowledge Library, a database containing relevant genome sequence information and data from gene expression studies.
¿ Synsorb Biotech Inc., of Calgary, Alberta, said the FDA authorized the company to provide the Children's Hospital of Wisconsin in Milwaukee with emergency doses of Synsorb Pk, an FDA fast-tracked drug designed to prevent complications associated with VTEC infections. The move is intended to prevent complications associated with a recent E. coli outbreak at the hospital. Synsorb Pk demonstrated an inhibitive effect against hemolytic uremic syndrome when administered within 48 hours of symptom expression in Phase III clinical trials.
¿ Techniclone Corp., of Tustin, Calif., said it will include Northwestern University, of Chicago, in an ongoing Phase II clinical study of Cotara treatment in patients with recurrent and newly diagnosed gliosblastoma and anaplastic astrocytoma. Cotara is one of Techniclone's collateral targeting technologies. It is designed to attack solid tumor cell structures and types rather than surface cancer cells.
¿ Xenova Group plc, of Slough, UK, said that 52 percent of available units had been sold in an open offer of units consisting of five ordinary shares and four warrants. Units were priced at 345 pence (US$5.18) per unit. About 1.5 million units were sold in the financing, which yielded the company about $11.7 million. (See BioWorld Today, July 14, 2000, p. 1.)